UBS Upgrades Medtronic to Neutral, Raises Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Danielle Antalffy has upgraded Medtronic (NYSE:MDT) from Sell to Neutral and raised the price target from $76 to $90.
August 15, 2024 | 11:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS analyst Danielle Antalffy has upgraded Medtronic from Sell to Neutral and raised the price target from $76 to $90.
The upgrade from Sell to Neutral and the increased price target from $76 to $90 by UBS is likely to have a positive short-term impact on Medtronic's stock price as it reflects improved analyst sentiment and potential for higher valuation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100